Publication | Open Access
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
33
Citations
14
References
2023
Year
NCT02947165.
| Year | Citations | |
|---|---|---|
Page 1
Page 1